In a phase I clinical study with 15 stage III-IV NSCLC patients, Iversen et al. found IDO is frequently expressed in LUAD, and targeting IDO by a peptide vaccine reduced Tregs, enhanced CD8+ T cell function, and prolonged overall survival by 18.2 months (240). Here, IDO1 is linked to non-small cell lung carcinoma.